3.

The members of the ETF shall consist of: chairs or vice chairs, or both, of the scientific committees of the Agency, and other representatives of those committees; representatives of the working parties of the Agency, including representatives of the PCWP and representatives of the HCPWP; staff members of the Agency; representatives of the coordination group established in accordance with Article 27 of Directive 2001/83/EC; representatives of the Clinical Trials Coordination and Advisory Group established in accordance with Article 85 of Regulation (EU) No 536/2014; and other clinical trial experts who represent national competent authorities for medicinal products. The members of the ETF shall be nominated by the entities they represent. External experts may be appointed to the ETF on an ad hoc basis, as necessary, especially in the cases referred to in Article 5(3). Representatives of other Union bodies and agencies shall be invited on an ad hoc basis, as necessary, to participate in the work of the ETF, especially in the cases referred to in Article 5(3). The ETF shall be chaired by the representative of the Agency and co-chaired by the chair or vice-chair of the CHMP.

← art_15__para_2__text_2 · All articles · art_15__para_3__text_1 →

Source: EUR-Lex (Cellar) · retrieved 2026-11-06 · Text as adopted (Official Journal); later amendments are not incorporated in this text.